Acta Diabetologica

, Volume 51, Issue 2, pp 205–210 | Cite as

A 7-year follow-up retrospective, international, multicenter study of insulin pump therapy in children and adolescents with type 1 diabetes

  • Chiara Mameli
  • Andrea E. Scaramuzza
  • Josephine Ho
  • Roque Cardona-Hernandez
  • Larisa Suarez-Ortega
  • Gian Vincenzo Zuccotti
Original Article

Abstract

We evaluated the long-term glycemic control in children with type 1 diabetes, using continuous subcutaneous insulin infusion (CSII) for at least 5 years in three diabetes centers from three different countries: Canada, Italy and Spain. This was an observational retrospective multicenter cohort study. Subjects were included if they were followed at one of the participating centers, had type 1 diabetes, age 5–20 years at time of data collection and used CSII for more than 5 years. Data collected included gender, age, disease duration, age at CSII initiation, body mass index (BMI), hemoglobin A1c (HbA1c), insulin requirement and serious adverse events (SAE) at baseline and every 12 months during follow-up. One hundred fifteen patients were included in the study (55 % males), aged 5–20 years (mean: 13.5 ± 3.8 years), with mean diabetes duration of 6.3 ± 3.4 years, using CSII for mean of 6.9 ± 1.2 years (range 5–12 years.). HbA1c significantly improved after 1 year of CSII treatment and during follow-up (p = 0.02). When HbA1c was compared between countries, a difference was observed, with slightly lower values in Italy than in Canada and Spain (p = 0.04). When evaluated by gender, HbA1c was similar at baseline, but significantly improved only in males during all follow-up (p = 0.004). No significant differences were observed for BMI, insulin requirement or SAE. Insulin pump therapy is safe and effective in the pediatric population, although in this study, the major benefit in HbA1c was seen in males. The use of advanced pump features was associated with greater improvement in HbA1c.

Keywords

Adolescents Children Continuous subcutaneous insulin infusion Insulin pump therapy Type 1 diabetes 

Notes

Conflict of interest

A.E.S receives research support, and participates in advisory boards for Medtronic, no conflict of interest disclosed for this study; C.M., J.H., R.C.-H., L.S.-O., and G.V.Z. have no conflicts of interest to disclose.

References

  1. 1.
    The Diabetes Control Complication Trial (DCCT) Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 329:977–986CrossRefGoogle Scholar
  2. 2.
    UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837–853CrossRefGoogle Scholar
  3. 3.
    Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2652PubMedCrossRefGoogle Scholar
  4. 4.
    Monami M, Lamanna C, Marchionni N, Mannucci E (2010) Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol 47(Suppl 1):77–81PubMedCrossRefGoogle Scholar
  5. 5.
    Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J (2010) Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 20(1):CD005103Google Scholar
  6. 6.
    Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM, Insulin Aspart Pediatric Pump Study Group (2008) A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care 31:210–215PubMedCrossRefGoogle Scholar
  7. 7.
    Ahern JA, Boland EA, Doane R, Ahern JJ, Rose P, Vincent M, Tamborlane WV (2002) Insulin pump therapy in pediatrics: a safe alternative to safely lower HbA1c levels across all age groups. Pediatr Diabetes 3:10–15PubMedCrossRefGoogle Scholar
  8. 8.
    Yeh HC, Brown TT, Maruthur N et al (2012) Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med 157:336–347PubMedCrossRefGoogle Scholar
  9. 9.
    Sulli N, Shashaj B (2006) Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4-year follow-up. Diabet Med 23:900–906PubMedCrossRefGoogle Scholar
  10. 10.
    Scrimgeour L, Cobry E, McFann BS, Burdick P, Weimer C, Slover R, Chase HP (2007) Improved glycemic control after long-term insulin pump use in pediatric patients with type 1 diabetes. Diabetes Technol Ther 9:421–428PubMedCrossRefGoogle Scholar
  11. 11.
    Shalitin S, Gil M, Nimri R, de Vries L, Gavan MY, Phillip M (2010) Predictors of glycemic control in patients with type 1 diabetes commencing continuous subcutaneous insulin infusion therapy. Diabet Med 27:339–347PubMedCrossRefGoogle Scholar
  12. 12.
    Hughes CR, McDowell N, Cody D, Costigan C (2012) Sustained benefits of continuous subcutaneous insulin infusion. Arch Dis Child 97:245–247PubMedCrossRefGoogle Scholar
  13. 13.
    Batajoo RJ, Messina CR, Wilson TA (2012) Long-term efficacy of insulin pump therapy in children with type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol 4:127–131PubMedCrossRefGoogle Scholar
  14. 14.
    Weinzimer SA, Ahern JH, Doyle EA, Vincent MR, Dziura J, Steffen AT, Tamborlane WV (2004) Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up study. Pediatrics 114:1601–1605PubMedCrossRefGoogle Scholar
  15. 15.
    Walsh J, Roberts R, Bailey T (2011) Guidelines for optimal bolus calculator settings in adults. J Diabetes Sci Technol 5:129–135PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    O’Connell MA, Donath S, Cameron FJ (2011) Poor adherence to integral daily tasks limits the efficacy of CSII in youth. Pediatr Diabetes 12:556–559PubMedGoogle Scholar
  17. 17.
    Cukierman-Yaffe T, Konvalina N, Cohen O (2011) Key elements for successful intensive insulin pump therapy in individuals with type 1 diabetes. Diabetes Res Clin Pract 92:69–73PubMedCrossRefGoogle Scholar
  18. 18.
    Scaramuzza AE, Iafusco D, Santoro L, Bosetti A, De Palma A, Spiri D, Mameli C, Zuccotti GV (2010) Timing of bolus in children with type 1 diabetes using continuous subcutaneous insulin infusion (TiBoDi Study). Diabetes Technol Ther 12:149–152PubMedCrossRefGoogle Scholar
  19. 19.
    Luijf YM, van Bon AC, Hoekstra JB, DeVries JH (2010) Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care 33:2152–2155PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    De Palma A, Giani E, Iafusco D, Bosetti A, Macedoni M, Gazzarri A, Spiri D, Scaramuzza AE, Zuccotti GV (2011) Lowering postprandial glycemia in children with type 1 diabetes after Italian pizza ‘margherita’ (TyBoDi2 Study). Diabetes Technol Therap 13:483–487CrossRefGoogle Scholar
  21. 21.
    Cherubini V, Gesuita R, Bonfanti R, Franzese A, Frongia AP, Iafusco D, Iannilli A, Lombardo F, Rabbone I, Sabbion A, Salvatoni A, Scaramuzza A, Schiaffini R, Sulli N, Toni S, Tumini S, Mosca A, Carle F; VIPKIDS Study Group. (2013) Health-related quality of life and treatment preferences in adolescents with type 1 diabetes. The VIPKIDS study. Acta Diabetol [Epub ahead of print]Google Scholar
  22. 22.
    Maniatis AK, Toig SR, Kingensmith GJ, Fay-Itzkowitz E, Chase HP (2001) Life with continuous subcutaneous insulin infusion (CSII) therapy: child and parental perspectives and predictors of metabolic control. Pediatr Diabetes 2:51–57PubMedCrossRefGoogle Scholar
  23. 23.
    Ahern JA, Boland EA, Doane R, Ahern JJ, Vincent M, Tamborlane WV (2002) Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatr Diabetes 3:10–15PubMedCrossRefGoogle Scholar
  24. 24.
    Plotnick LP, Clark LM, Brancati F, Erlinger T (2003) Diabetes Care 26:1142–1146PubMedCrossRefGoogle Scholar
  25. 25.
    Willi SM, Planton J, Egede L, Schwarz S (2003) Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr 143:796–801PubMedCrossRefGoogle Scholar
  26. 26.
    De Wit M, Snoek FJ (2011) Depressive symptoms and unmet psychological needs of Dutch youth with type 1 diabetes: results of a web-survey. Pediatr Diabetes 12(3 pt 1):172–176PubMedCrossRefGoogle Scholar
  27. 27.
    de Vries L, Grushka Y, Lebenthal Y, Shalitin S, Phillip M (2011) Factors associated with increased risk of insulin pump discontinuation in pediatric patients with type 1 diabetes. Pediatr Diabetes 12(5):506–512PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2013

Authors and Affiliations

  • Chiara Mameli
    • 1
  • Andrea E. Scaramuzza
    • 1
  • Josephine Ho
    • 2
  • Roque Cardona-Hernandez
    • 3
  • Larisa Suarez-Ortega
    • 3
  • Gian Vincenzo Zuccotti
    • 1
  1. 1.Department of Pediatrics, Azienda OspedalieraUniversity of MilanoMilanItaly
  2. 2.Department of Pediatrics, Faculty of MedicineUniversity of CalgaryCalgaryCanada
  3. 3.Division of Endocrinology and DiabetesHospital Sant Joan de DéuBarcelonaSpain

Personalised recommendations